






This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.



## Opportunities through geographical expansion





## Path to the 2025 target from 2021 onwards



Building blocks for growth

Unknowns

Headwinds



Organic growth in all units

Geographical expansion

In-licensing & M&As are options in all units



Darolutamide ARASENS\* & ARANOTE\*

Easyhaler® tiotropium\*

Possible changes in regulation (pricing etc.)










Comtess

Loss of distribution agreement in Animal Health





**Orion Corporation Capital Markets Day** 

